Last edition
News about "DEGEVMA US FDA approval"
US FDA Approves Teva's Denosumab Biosimilar DEGEVM
Teva’s DEGEVMA, a denosumab biosimilar to Xgeva, has gained US FDA approval for cancer-related bone complications and other indications.
DEGEVMA US FDA Approval | 30/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members